The introduction of sodium-glucose cotransporter-2 (SGLT2) inhibitors marked a paradigm shift in managing diabetic nephropathy due to their proven ability to slow renal function decline and reduce albuminuria [1]. The gene discussed is SLC5A2; the disease is diabetic kidney disease.